In the news
Media coverage of health and science topics
The Scientist Sept. 24, 2021
Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?
Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.
Read more at The Scientist
Behind the headlines
Research findings and data from the National Library of Medicine
PubMed articles
BMJ AUG. 20, 2021
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
H Chung et al
Two doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed …
Lancet Infect Dis SEPT. 7, 2021
Hospitalisation among vaccine breakthrough COVID-19 infections
PV Juthani et al
Vaccine JULY 22, 2021
Evidence for antibody as a protective correlate for COVID-19 vaccines
KA Earle et al
A correlate of protection (CoP) is urgently needed to expedite development of additional COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody …
JAMA AUG. 30, 2021
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
D Steensels et al
This study compares the immune responses to the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines in health care workers in Belgium.
JAMA Netw Open SEPT. 1, 2021
Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
NE Richards et al
This cohort study compares antibody responses in a cohort in which both BNT162b2 and mRNA-1273 COVID-19 vaccines were administered.
Am J Kidney Dis JAN. 1, 2021
Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
JJ Broseta et al
Immunization with mRNA vaccines generated a humoral and cellular immune response in a high proportion of patients with kidney failure receiving maintenance dialysis. Thes …
Liver Transpl AUG. 18, 2021
Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients
AT Strauss et al
Prior studies have demonstrated a decreased humoral response in solid organ transplant recipients (SOTRs) to SARS‐CoV‐2 mRNA vaccination (17% antibody response after dose …
Cancer Cell SEPT. 13, 2021
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
M Mairhofer et al
Science SEPT. 14, 2021
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
J Mateus et al
[Figure: see text].
Related content
Similar articles
Reviews
People also viewed
Also of interest
Additional recent and related news
The New York Times SEPT. 22, 2021
Moderna vs. Pfizer: Both Knockouts, but One Seems to Have the Edge
A series of studies found that the Moderna vaccine seemed to be more protective as the months passed than the Pfizer-BioNTech vaccine. Here’s why.
The New York Times DEC. 20, 2021
Parents Grapple With How Long to Wait for Their Children’s Second Shots
Waiting eight weeks or more between doses may boost immunity. But as Omicron slams the United States, waiting also comes with risks.
NIH Research Matters OCT. 19, 2021
Moderna COVID-19 vaccine generates long-lasting immune memory
People who received low doses of the Moderna COVID-19 vaccine had strong immune memories of the virus six months after being fully vaccinated.
The New York Times JULY 4, 2021
Should People With Immune Problems Get Third Vaccine Doses?
France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like these are on their own.
The Scientist AUG. 11, 2022
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines
Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.
